NACDS testified this week at a Food and Drug Administration (FDA) Opioid Policy Steering Committee public meeting on ways the agency can strengthen its oversight of opioids.
NACDS Submits Comments to President’s Commission on Combating Drug Addiction and the Opioid Crisis Describes pharmacy as working partner for solutions
NACDS President and CEO Steven C. Anderson, IOM, CAE, submitted official comments to the President’s Commission on Combating Drug Addiction and the Opioid Crisis, which reflect NACDS’ commitment to help address prescription drug abuse, addiction and proper access.
NACDS and the American Pharmacists Association (APhA) sent a letter to President Donald Trump this week, urging him to reject proposals allowing importation of non-FDA approved drugs
FDA Announced Class-Wide Drug Labeling Changes Warning of Risks of Combining Opioids and Anxiety Meds
The Food and Drug Administration (FDA) announced class-wide drug labeling changes for opioid and benzodiazepine products on August 31 to help patients and doctors better understand the potentially life-threatening risks of […]
NACDS Highlights Role of Pharmacist-Provided Vaccine Services in Lead-Up to Congressional Healthcare Innovation Forum
NACDS Highlights Role of Pharmacist-Provided Vaccine Services in Lead-Up to Congressional Healthcare